FDA to Amarin: No Appeal for You
Amarin continues to suffer from data from trials of AbbVie's and Merck's drugs, unable to compete with GlaxoSmithKline until Vascepa's label is expanded.
These 3 Catalysts Could Unlock Inovio's True Value
Will these three catalysts -- a short-term one, a long-term one, and a wild card -- boost Inovio’s value and stabilize its long-term growth potential? Let’s analyze how Roche, Merck, and GlaxoSmithKline all factor into Inovio's future.